Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

COVID-19 Vaccine Manufacturers Submit Appeals to FDA for Fourth Dose
COVID-19 Vaccine Manufacturers Submit Appeals to FDA for Fourth Dose
The makers behind two of the largest COVID-19 vaccines, Pfizer, BioNTech, and Moderna, are seeking FDA approval for a fourth dose of their respective COVID-19 vaccines. Pfizer and BioNTech submitted a...
NICE Recommends Elosulfase Alfa for Morquio A Syndrome
NICE Recommends Elosulfase Alfa for Morquio A Syndrome
The UK’s National Institute for Health and Care Excellence (NICE) has recommended the routine use of BioMarin’s Vimizin (elosulfase alfa) by the National Health Service (NHS) for patients with ...
FDA Approves Opdualag for Unresectable or Metastatic Melanoma
FDA Approves Opdualag for Unresectable or Metastatic Melanoma
On March 18, 2022, FDA approved Bristol-Myers Squibb Company’s Opdualag (nivolumab and relatlimab-rmbw) for use in adults and pediatric patients 12 years of age or older with unresectable or meta...
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY for CDKL5 Deficiency Disorder
Marinus Pharmaceuticals Announces FDA Approval of ZTALMY for CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, a biopharmaceutical company focused on the development of treatments for seizure disorders, announced on March 18, 2022 that FDA has approved ZTALMY (ganaxolone) for the t...
NHS fast-tracks new targeted drug for rare lung cancer
NHS fast-tracks new targeted drug for rare lung cancer

Patients eligible to receive Takeda’s Exkivity (mobocertinib) have a rare form of lung cancer that cannot be removed by surgery

Brazil Study Finds Ivermectin Did Not Reduce Hospital Admissions
Brazil Study Finds Ivermectin Did Not Reduce Hospital Admissions

A newly reported study has provided more evidence that ivermectin is ineffective as a treatment for COVID-19 infection.

Merck KGaA to Pay Over $3 Million to Patients After Thyroid Drug Formulation Change
Merck KGaA to Pay Over $3 Million to Patients After Thyroid Drug Formulation Change
France’s highest court has ordered European drugmaker Merck KGaA to pay more than $3.6 million to patients who received a thyroid drug Levothyrox (levothyroxine sodium) with diminished quality f...
Medicines Patent Pool Inks Deal With 35 Companies for Generic Paxlovid
Medicines Patent Pool Inks Deal With 35 Companies for Generic Paxlovid
The United Nations-backed Medicines Patent Pool (MPP) has signed agreements with 35 companies to manufacture generic versions of Pfizer’s COVID-19 therapeutic Paxlovid (nirmatrelvir). ...
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
RINVOQ® (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active ulcerative c...
Roche Posts Positive Results for Evrysdi in Type 2 and 3 Spinal Muscular Atrophy
Roche Posts Positive Results for Evrysdi in Type 2 and 3 Spinal Muscular Atrophy
Roche has published long-term data confirming the efficacy and safety of its drug Evrysdi (risdiplam) in patients age two to 25 who have type 2 or type 3 spinal muscular atrophy, a rare and often ...
Allarity Therapeutics Requests Type C Meeting With FDA to Discuss Dovitinib in Third-Line RCC
Allarity Therapeutics Requests Type C Meeting With FDA to Discuss Dovitinib in Third-Line RCC
Allarity Therapeutics, Inc. has filed a formal request with the FDA to hold a Type C meeting where they can discuss possible clinical paths to support the approval of dovitinib in renal cell carci...
Exelixis Shuts Down sNDA Plans for Cabometyx Following Negative Phase 3 Study Results
Exelixis Shuts Down sNDA Plans for Cabometyx Following Negative Phase 3 Study Results
Exelixis announced that it has scrapped plans to submit a supplemental new drug application (sNDA) for its cancer therapy Cabometyx (cabozantinib) for the treatment of newly diagnosed hepatocellul...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand